本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

ADC Therapeutics SA

1.71
-0.0850-4.75%
成交量:21.88萬
成交額:37.41萬
市值:1.65億
市盈率:-0.73
高:1.78
開:1.76
低:1.67
收:1.79
資料載入中...

公司資料

公司名字:
ADC Therapeutics SA
交易所:
NYSE
成立時間:
2011
員工人數:
274
公司地址:
BiopOle,Route de la Corniche 3B,Epalinges,Vaud,Switzerland
郵編:
1066
傳真:
- -
簡介:
ADC Therapeutics SA於2011年6月6日根據瑞士法律註冊成立。該公司是一家完全整合的商業階段生物技術公司,通過下一代靶向抗體藥物偶聯物幫助改善癌症患者的生活。該公司的旗艦產品ZYNLONTA(loncastuximab tesirine或Lonca)於2021年4月23日獲得FDA的加速批准,並在此後不久在美國上市,用於治療經過兩個或兩個以上系統治療的複發或難治性大B細胞淋巴瘤成人患者,包括未另行說明的瀰漫性大B細胞淋巴瘤、由低級別淋巴瘤引起的DLBCL,以及高級別B細胞淋巴瘤。該公司的目標是將ZYNLONTA確立為三線+ DLBCL護理標準,同時探索ZYNLONTA在早期治療和組合中的應用,以擴大市場機會。

董事

名稱
職位
Christopher Martin
Chief Executive Officer and Director
Michael Forer
Executive Vice President, Chief Financial Officer and Vice Chairman of the Board, General Counsel
Ron Squarer
Chairman of the Board of Director
Jacques Theurillat
Director
Peter B. Corr
Director
Peter Hug
Director
Stephen Evans Freke
Director
Thomas M. Rinderknecht
Director
Thomas Pfisterer
Director
Tyrell J. Rivers
Director
Victor Sandor
Director

股東

名稱
職位
Christopher Martin
Chief Executive Officer and Director
Jay Feingold
Senior Vice President, Chief Medical Officer & Head of Oncology
Jennifer Herron
Senior Vice President, Chief Commercial Officer
Michael Forer
Executive Vice President, Chief Financial Officer and Vice Chairman of the Board, General Counsel
Patrick van Berkel
Senior Vice President, Research and Development
Peter Greaney
Head of Corporate Development
Richard Onyett
Vice President, Business Development
Stephane Henchoz
Director of Finance
Susan Romanus
Chief Compliance Officer